suPAR is proven to be a significant marker in predicting 30-day and 90-day mortality in ED patients
Thu Jan 25 2024
The role of soluble urokinase type plasminogen activator receptor (suPAR) in predicting mortality, readmission, length of stay and discharge in emergency patients: A systematic review and meta-analysis
This meta-analysis focuses on identifying the impact of high suPAR concentrations in patients presented at the ED and the outcomes.
Background
Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker that predicts mortality, readmission, early discharge, and length of hospital stay (LOS), thus serving as a useful tool for ED physicians. The study aims to analyze the efficacy of suPAR in predicting these prognostic markers in ED.
Methods
A comprehensive search on 6 databases from the inception to 30th November 2022 was performed to select the following eligibility criteria:
- Observation or triage trial studies investigating the role of suPAR levels in predicting 30-day and 90-day mortality
- 30-day readmission
- Early discharge (within 24hr)
- LOS in patients coming to acute medical units (AMU).
Conclusions
A high suPAR level at admission to ED is a sign of a serious condition and attributes to higher risks of mortality and readmission. Plasma suPAR levels may thus be useful for evaluating medical patients who have been admitted to the AMU to ascertain whether they need a more thorough clinical evaluation as well as intensive monitoring and care. Further trials and investigations must verify suPAR’s prognostic use in emergency settings clinically.
